RNA-binding Raly-like protein (RALYL)

RNA-binding Raly-like protein (RALYL) is a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family, recognized for its RNA-binding properties and involvement in post-transcriptional regulation, including mRNA stability, alternative splicing, and mRNA processing[1][2][5]. RALYL is predominantly nuclear and is especially expressed in liver progenitor cells and certain cancer types[2][5]. Elevated RALYL expression is associated with enhanced tumor proliferation, self-renewal, chemoresistance, metastatic potential, and regulation of epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma and other malignancies[2][1]. RALYL exerts its oncogenic effects by stabilizing specific mRNAs (notably TGF-β2) via modulation of m6A methylation, thus activating TGF-β and downstream PI3K/AKT and STAT3 signaling, which are key to cancer stemness maintenance[2]. RALYL expression correlates with poor prognosis and advanced disease in several cancers, implicating it as a potential diagnostic and therapeutic target[2][1]. There are currently no known drugs that directly target RALYL, nor established biomarkers or safety concerns specifically tied to this molecule[5][2].

Other names

HNRPCL3hRALYLheterogeneous nuclear ribonucleoprotein C-like 3hnRNP core protein C-like 3RNA-binding Raly-like proteinRALY RNA binding protein like